By Fineline Cube Akeso, Inc. (HKG: 9926) announced positive Phase II data from the COMPASSION-26 trial evaluating cadonilimab, its proprietary PD-1/CTLA-4 bispecific antibody (BsAb), in combination with chemotherapy for first-line advanced pancreatic ductal adenocarcinoma (PDAC). Results were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Clinical Trial Snapshot
| Parameter | Detail |
|---|---|
| Study | COMPASSION-26 (Phase II) |
| Population | Treatment-naïve advanced PDAC patients |
| Regimen | Cadonilimab + standard chemotherapy |
| Mechanism | Simultaneous blockade of PD-1 and CTLA-4 on T cells |
| Key Finding | Durable responses observed in both PD-L1+ and PD-L1– subgroups |
| Tumor Microenvironment | Activity demonstrated in immunologically “cold” and IO-resistant tumors |
Drug Profile & Differentiation
- Molecule Type: First-in-class tetravalent bispecific IgG1 antibody
- Targets: PD-1 (immune checkpoint) + CTLA-4 (T-cell priming regulator)
- Innovation: Engineered for reduced systemic toxicity vs. combo monotherapies while maintaining synergistic anti-tumor efficacy
- Broad Applicability: Clinically active across PD-L1 expression statuses—a key limitation of many existing immunotherapies
Guideline Adoption & Indications
To date, cadonilimab has been strongly recommended in over 20 clinical guidelines and consensus documents across China and Asia-Pacific, covering:
- Gastric cancer
- Gynecological tumors (e.g., cervical, ovarian)
- Hepatocellular carcinoma
- Esophageal squamous cell carcinoma
- Nasopharyngeal carcinoma
- Biliary tract cancer
- Now under evaluation: First-line PDAC
Pancreatic cancer remains one of oncology’s most challenging indications, with 5-year survival below 12%. The COMPASSION-26 data suggest cadonilimab may offer a meaningful advance in this high-unmet-need setting.
Strategic Outlook
- Regulatory Path: Akeso plans to initiate global Phase III trials in PDAC by Q4 2026
- Commercial Potential: With guideline backing in 7+ tumor types, cadonilimab is positioned as a backbone IO agent in China’s immuno-oncology landscape
- Partnership Leverage: Existing co-development agreements (e.g., with Summit Therapeutics) may expand into pancreatic cancer indications
Forward‑Looking Statements
This report contains forward-looking information regarding clinical development timelines, regulatory strategy, and commercial potential. Actual outcomes may vary due to trial results, regulatory decisions, and competitive dynamics in the global IO market.-Fineline Info & Tech